HOME >> MEDICINE >> NEWS
Sealing corneal incisions with a drop of chemistry, BU researchers develop gel for cataract surgery

(Boston) -- By introducing just the right biocompatible molecules to one another, a research team led by Mark Grinstaff, an associate professor of biomedical engineering and of chemistry at Boston University, has produced an elastic, transparent gel that sets so fast and adheres so surely to the eye's surface that it could soon become the first and best choice for sealing corneal incisions.

The substance, known as a hydrogel, promises to be a useful tool in the kit used for the most common of ophthalmic surgeries: cataract removal. Currently, 11 million such surgeries are performed worldwide annually, a figure expected to increase as the world's population grows older.

The team's findings will appear in the October 13 issue of the Journal of the American Chemical Society.

A cataract is a clouding of the eye's lens, a condition that obscures vision by gradually blocking the light that enters the eye. To remove a clouded lens, a surgeon makes a small incision in the conjunctiva, the margin between white area (tunica) and the clear area (cornea) of the outer eye. Through this tiny opening, the surgeon works to break up the lens, often by using high-frequency sound waves; extracts the destroyed lens; then implants a synthetic lens. Currently, the procedure finishes with the surgeon following one of two accepted paths: allowing the incision to seal itself or stitching the incision shut using nylon sutures.

Each closing method has its drawbacks. Self-sealing, in which the open wound closes gradually over time, carries the risk of infection as well as leakage of intraocular fluid. Suturing likewise can carry the risk of infection and inflammation, as well as the abnormal development of blood vessels, a condition known as vascularization.

To potentially stave off these post-operative complications, Grinstaff's team decided to build a biological bandage using versatile materials known as dendritic macromolecules. Ca
'"/>

Contact: Ann Marie Menting
amenting@bu.edu
617-358-1240
Boston University
12-Oct-2004


Page: 1 2 3

Related medicine news :

1. 7-month-old is youngest recipient of artificial corneal transplant
2. A&E departments could help resolve the national shortage of corneal donors
3. Wolfgang Glasser receives ACS award for wood chemistry, bio-based composites research
4. Indiana University researchers closer to helping hearing-impaired using stem cells
5. Protein that helps skin cancer spread identified by Stanford researchers
6. US life expectancy about to decline, researchers say
7. Gene for age-related macular degeneration discovered by Yale researchers
8. Dartmouth researchers find where musical memories are stored in the brain
9. Columbia researchers receive $3 million to combat genetic killer of infants & toddlers
10. US cancer researchers launch first American-Israeli cancer conference
11. USC dental researchers develop first test for predicting cavities in children

Post Your Comments:
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... (HealthDay News) -- Lack of sleep not only puts teens ... increased risk for obesity, researchers warn. The study authors ... were aged 16 and 21. Nearly one-fifth of them got ... were age 16, and this group was 20 percent more ... got more than eight hours of sleep per night at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... August 28, 2014 As Mirena IUD ... around the U.S., Bernstein Liebhard LLP notes that a ... like Mirena as ideal birth control for teenage girls. ... authors of the study point out that IUDs are ... other methods favored by this patient population. Their study, ...
Breaking Medicine News(10 mins):Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
Cached News: